FDA Approves Innovations in Rapid Testing for Drug-Resistant Pathogens
FDA Approves Innovations in Rapid Testing for Drug-Resistant Pathogens
In an encouraging advancement in the battle against Antimicrobial Resistance (AMR), NG Biotech, in collaboration with Hardy Diagnostics, has announced a significant achievement: the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to two cutting-edge rapid diagnostic tests. These tests, the NG-TEST® Candida auris and NG-TEST® Acineto-5®, aim to tackle critical and life-threatening pathogens that pose serious global health risks.
Understanding the Breakthrough Designation
The Breakthrough Device Designation is a recognition by the FDA for technologies that promise to address significant unmet medical needs and have the potential to alleviate life-threatening conditions. By granting this designation, the FDA highlights the urgency and necessity of these new diagnostic tools in healthcare environments plagued by drug-resistant infections.
Targeting Drug-Resistant Pathogens
The two rapid tests are designed to detect pathogens that the World Health Organization (WHO) has classified as critical priorities for addressing AMR. First among them is Candida auris, a multidrug-resistant yeast that has been linked to numerous outbreaks in healthcare settings across the globe. Listed in the WHO’s Fungal Priority Pathogens List, Candida auris is notoriously difficult to identify and is associated with high mortality rates due to its rapid spread in hospitals.
The other test, NG-TEST® Acineto-5®, is targeted at Carbapenem-resistant Acinetobacter baumannii (CRAB), a highly dangerous bacterial strain recognized on the WHO's Bacterial Priority Pathogens List. This bacterium is particularly concerning due to its capacity for rapid transmission in healthcare scenarios and its formidable resistance profile.
Rapid and Reliable Results
The NG-TEST® Candida auris is heralded as the first rapid lateral flow immunoassay specifically engineered to identify this dangerous yeast from cultured samples within a remarkable 15-minute timeframe. Independent published data endorses its efficacy, demonstrating complete concordance with established reference methods across various isolates. This accuracy supports its critical role in outbreak management and infection control efforts in hospitals.
Similarly, NG-TEST® Acineto-5® quickly detects and differentiates five notable carbapenemase families, namely OXA-23-like, OXA-24/143-like, OXA-58-like, VIM, and NDM from Acinetobacter samples in under 15 minutes. The assay is designed for straightforward usability and does not require specialized equipment, making it highly practical for rapid deployment in hospital laboratories.
Industry Reaction and Future Implications
Milovan Stankov-Pugès, CEO of NG Biotech, applauded the breakthrough designation, emphasizing that it affirms not only the robustness of the technology behind these assays but also the pressing need they fulfill in clinical settings. Andre Hsiung, Chief Scientific Officer at Hardy Diagnostics, echoed these sentiments, underscoring the increasing urgency for prompt detection methods in the fight against multidrug-resistant organisms that represent significant risks in healthcare.
Manufactured in France by NG Biotech, the tests are currently undergoing FDA review, available solely for research use at this time. The goal of these devices is to accelerate pathogen detection, reinforcing efforts in surveillance, driving informed infection control measures, and supporting global initiatives aimed at combating antimicrobial resistance. By enhancing the speed of diagnosis, healthcare systems can improve their response to outbreaks, ultimately protecting patient safety and saving lives.
In conclusion, the recent FDA designations for NG Biotech's rapid diagnostic tests signify a hopeful advance in public health and the ongoing fight against drug-resistant infections. With the increasing prevalence of antimicrobial resistance, such innovations are not just timely—they are essential for protecting public health and enhancing infection control practices in healthcare environments worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.